Alpelisib

Alpelisib is a selective PI3Kα inhibitor, a medication used for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, PIK3CA-mutated, advanced breast cancer. Alpelisib works by targeting and inhibiting the PI3Kα enzyme, which is commonly found to be overactive in cancers. This enzyme plays a key role in the growth and survival of cancer cells, making it an attractive therapeutic target for personalized cancer treatments.
The drug is typically prescribed for patients whose cancer has progressed or returned after other treatments, and who have been found to have specific mutations in the PIK3CA gene. By targeting these mutations, Alpelisib aims to block the abnormal growth signals that contribute to cancer, thereby slowing down the disease’s progression.
Alpelisib is used in combination with the hormonal therapy drug, fulvestrant, for the treatment of HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer that has progressed after prior endocrine therapy. The combination therapy aims to address both hormonal and cellular signaling pathways to provide a more effective treatment option for these patients.
Before starting Alpelisib treatment, patients should be carefully assessed to ensure its suitability. Patients should also be monitored for potential side effects, which may include diarrhea, rash, and elevations in liver enzymes. Healthcare professionals should discuss the risks and benefits of the treatment with each patient and closely monitor their progress during therapy.